Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | VCAM1 | P19320 | 6/20 | 0.42 |
| ▸ | PGK1 | P00558 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MERTK | Q12866 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8461057 | 0.85 | TSHR (0.59) | TSHRALDH1A1MAPK1CYP3A4VCAM1 | |
| SCHEMBL29790171 | 0.84 | TSHR (0.50) | TSHRALDH1A1MAPK1CYP3A4VCAM1 | |
| SCHEMBL1626023 | 0.84 | TSHR (0.50) | TSHRALDH1A1MAPK1CYP3A4VCAM1 | |
| SCHEMBL359519 | 0.80 | TSHR (0.60) | TSHRALDH1A1MAPK1CYP3A4VCAM1 | |
| SCHEMBL10254398 | 0.79 | ALDH1A1 (0.51) | TSHRALDH1A1MAPK1CYP3A4VCAM1 | |
| SCHEMBL9282606 | 0.78 | TSHR (0.42) | TSHRALDH1A1MAPK1CYP3A4VCAM1 | |
| SCHEMBL2211091 | 0.78 | CYP1A2 (0.57) | TSHRALDH1A1MAPK1CYP3A4VCAM1 | |
| SCHEMBL9180125 | 0.78 | TSHR (0.62) | TSHRALDH1A1MAPK1CYP3A4VCAM1 | |
| SCHEMBL10759125 | 0.76 | ALDH1A1 (0.50) | TSHRALDH1A1CYP3A4GPR35SNCA | |
| SCHEMBL18138428 | 0.76 | TSHR (0.47) | TSHRALDH1A1MAPK1CYP3A4VCAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431747-B2 | Process for the preparation of monomers for polybenzimidazole materials | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-04-30 | — | — | US | disclosed |
| US-20100160686-A1 | Process for the Preparation of Monomers for Polybenzimidazole Materials | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160686-A1 | Process for the Preparation of Monomers for Polybenzimidazole Materials | PBRM1, PUF60, PARG | TSHR 4626/4885ALDH1A1 2542/4885MAPK1 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.